Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study

MLA

Rodrigo Milán Pinilla, et al. “Effectiveness and Safety of PCSK9 Inhibitors in Real-World Clinical Practice. An Observational Multicentre Study. The IRIS-PCSK9I Study.” Atherosclerosis Plus, vol. 45, Nov. 2021, pp. 32–38. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2169b116cf8566849cf4241055ffa2d5&authtype=sso&custid=ns315887.

APA

Rodrigo Milán Pinilla, María Magdalena Carrillo Bailén, Marina Blanco-Ruiz, María Josefa Álvarez Soria, Belén Sánchez Rodríguez, Patricia Martínez-Sánchez, Laura Amaya-Pascasio, Roberto Valverde Moyano, Irene Pérez Ortega, María Victoria Mejías Olmedo, Pablo González Bustos, Javier Fernández Pérez, Purificación Sánchez López, Reyes de Torres Chacón, Eduardo Agüera Morales, Manuel Payán Ortiz, Luis Andrade Zumárraga, Antonio Arjona-Padillo, Alba María Castillo Fernández, … Ricardo Roa Chamorro. (2021). Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study. Atherosclerosis Plus, 45, 32–38.

Chicago

Rodrigo Milán Pinilla, María Magdalena Carrillo Bailén, Marina Blanco-Ruiz, María Josefa Álvarez Soria, Belén Sánchez Rodríguez, Patricia Martínez-Sánchez, Laura Amaya-Pascasio, et al. 2021. “Effectiveness and Safety of PCSK9 Inhibitors in Real-World Clinical Practice. An Observational Multicentre Study. The IRIS-PCSK9I Study.” Atherosclerosis Plus 45 (November): 32–38. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2169b116cf8566849cf4241055ffa2d5&authtype=sso&custid=ns315887.